Cevdet Serkan GÖKKAYA, Cüneyt ÖZDEN, Çetin Volkan ÖZTEKİN, Ali MEMİŞ, Binhan Kağan AKTAŞ, Emin ÖZTÜRK

Insulin resistance impairs response to doxazosin therapy in men with benign prostatic hyperplasia

To evaluate the effects of insulin resistance (IR) on outcomes of doxazosin treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: This prospective study included 64 patients with LUTS due to BPH. LUTS were evaluated using the international prostate symptom score (IPSS) and maximum flow rate (Qmax) in uroflowmetry. Diagnosis of IR was achieved using homeostasis model assessment (HOMA) score and patients were grouped with respect to absence (group 1, n = 44) or presence (group 2, n = 20) of IR. Patients were evaluated before and after 3 months of daily doxazosin therapy (4 mg extended release tablet). Results: Doxazosin significantly improved the IPSS and Qmax in group 1 (P = 0.04 and P = 0.008, respectively). In group 2, doxazosin treatment had no significant therapeutic effect on mean IPSS and Qmax (P = 0.116 and P = 0.477, respectively). On the other hand, doxazosin significantly improved mean HOMA scores of patients with IR (P = 0.015). Conclusion: IR impairs response to doxazosin treatment for LUTS due to BPH. The presence of IR should be kept in mind in patients refractory to doxazosin therapy.

Anahtar Kelimeler:

Key words: Insulin resistance, benign prostatic hyperplasia, doxazosin

Insulin resistance impairs response to doxazosin therapy in men with benign prostatic hyperplasia

Keywords:

Key words: Insulin resistance, benign prostatic hyperplasia, doxazosin,

PDF

___

Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder 2010; 5: 212–8.
Robertson C, Link CL, Onel E, Mazzetta C, Keech M, Hobbs R et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007; 99: 347–54.
Kaplan SA. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int 2008; 102 [Suppl 2]: 3–7.
Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P et al. Proscar Long-Term Efficacy and Safety Study Group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001; 57: 1073–7.
Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403–5.
Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003; 15: 165–74.
Geller J. Overview of benign prostatic hypertrophy. Urology 1989; 34 [Suppl 4]: 57–63.
Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7–12.
Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370: 89–93.
Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109 [Suppl 2]: 135–48.
Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151–8.
Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009; 12: 160–5.
Ueshiba H, Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003; 35: 532–6.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
Şahin M, İnal BB, Öğreden Ş, Yiğit Ö, Aral H, Güvenen G. Metabolic profile and insulin resistance in patients with obstructive sleep apnea syndrome. Turk J Med Sci 2011; 41: 443–54.
Ayvaz DNÇ, Kılınç FN, Paç FA, Çakal E. Anthropometric measurements and body composition analysis of obese adolescents with and without metabolic syndrome. Turk J Med Sci 2011; 41: 267–74.
Akkiprik M, Özdemir Sertoğlu F, Çağlayan S, Aral C, Özışık G, Atabey Z et al. Association of ACP1 genotypes and clinical parameters in patients with metabolic syndrome. Turk J Med Sci 2011; 41: 533–41.
Bourke JB, Griffin JP. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 1966; 38: 18–23.
Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157–62.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199–203.
Teber D, Sofikerim M, Ates M, Gözen AS, Güven O, Sanli O et al. Is type 2 diabetes mellitus a predictive factor for incontinence after laparoscopic radical prostatectomy? A matched pair and multivariate analysis. J Urol 2010; 183: 1087–91.
Canda AE, Dogan H, Kandemir O, Atmaca AF, Akbulut Z, Balbay MD. Does diabetes affect distribution and number of interstitial cells and neuronal tissue in the ureter, bladder, prostate and urethra of humans? J Urol Suppl 2012; 187: e204–e205.
Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986; 61: 1081–90.
James S, Chapple CR, Phillips MI, Greengrass PM, Davey MJ, Turner-Warwick RT et al. Autoradiographic analysis of alpha- adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142: 438–44.
Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol 2010; 641: 75–81.
Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl 1996; 17: 2–4.
Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor I [IGF-I] causes growth of the rat prostate. J Urol 1997; 158: 222–7.
Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP. Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm Res 1996; 45: 252–7.
Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth factor I [IGF-I] in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177–81.
De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560–70.
Goldsmith DR, Plosker GL. Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. Drugs 2005; 65: 2037–47.
Acar D, Bozlu M, Doruk E, Akbay E, Çayan S, Ülger S et al. Comparison of the effects of four different alpha blockers on the lipid profile in patients with benign prostatic hyperplasia. Eur Urol Suppl 4, 2005; 3–7.
Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297–307.
Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992; 5: 827–31.
Nilsson PM, Lindholm LH, Schersten BF. Life style changes improve insulin resistance in hyperinsulinaemic subjects: a one- year intervention study of hypertensives and normotensives in Dalby. J Hypertens 1992; 10: 1071–8.